New hope for vulnerable patients: remdesivir trial targets RSV in Immune-Weakened individuals

NCT ID NCT06817889

First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 23 times

Summary

This study tests if the antiviral drug remdesivir can safely treat RSV (a common respiratory virus) in 60 adults whose immune systems are weakened by cancer treatments or autoimmune therapies. Participants must have a confirmed RSV infection with symptoms. The main goal is to see if remdesivir reduces the need for extra oxygen. This research is important because RSV can be severe in people with weak immune systems.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • City of Hope Comprehensive Cancer Center

    NOT_YET_RECRUITING

    Duarte, California, 91010, United States

    Contact

  • Fred Hutch/University of Washington Cancer Consortium

    RECRUITING

    Seattle, Washington, 98109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact

Conditions

Explore the condition pages connected to this study.